→ A troubled Aduro has recruited a Pfizer cancer R&D exec to take the chief medical officer’s job. Dimitry S.A. Nuyten is moving from his job as Vice President and Immuno-Oncology Clinical Development Leader to the biotech. His stint at Pfizer put Nuyten in charge of its Bavencio work, partnered with Merck KGaA. “We are extremely pleased to welcome Dimitry as we prepare to broaden our development plans for STING agonist ADU-S100 and initiate our first in human study of anti-APRIL antibody BION-1301 in IgA nephropathy,” noted CEO Stephen T. Isaacs in a statement.
→ Trevi Therapeutics $TRVI will soon set out to raise about $70 million in its IPO. The biotech set its terms at $14 to $16 a share, with plans to sell 4.67 million. Insiders are slated to pick up about $28 million of that load, according to Renaissance Capital.
→ Gritstone $GRTS reports that the FDA has cleared the way to jumpstart an early-stage study of its “off-the-shelf” neo-antigen drug for solid tumors. That will give the biotech time to report out on the first small batch of patients before the end of this year.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription